By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile



Corporate Headquarters
One Amgen Center Drive
Thousand Oaks  California  91320-1789  U.S.A.
Phone: 805-447-1000 Fax: 805-447-1010


Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.

Amgen focuses on areas of high unmet medical need and leverages its biologics manufacturing expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world's leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.

For more information, visit and follow us on

Key Statistics

Ownership: Public

Web Site: Amgen
Employees: 7,300+ Worldwide
Symbol: AMGN


Genesis Research and Development Corporation 

Phylos, Inc.  In 2000, Phylos entered into collaboration with Amgen to apply Phylos' PROfusion™ technology to rapidly identify high-affinity binding agents to potential therapeutic targets supplied by Amgen. Amgen will use the sequences and structural information gained through this collaboration for its internal drug discovery programs.

UCB, Inc.  Contract manufacturing of Abarelix peptide active ingredient

EPIX Pharmaceuticals, Inc. 

Dyax Corp.  Antibody phage display

Company News
Amgen (AMGN) Release: New Data Show Consistent Safety Profile For Up To 10 Years With Prolia (Denosumab) In Postmenopausal Women With Osteoporosis 10/13/2015 10:02:33 AM
Amgen (AMGN) Release: New Exploratory Analysis Showed Romosozumab Increased Estimated Bone Strength More Than Teriparatide 10/13/2015 7:44:21 AM
As Eli Lilly (LLY) Halts CETP Inhibitor Trial, Analyst Wonder if Amgen (AMGN) Wasted $300 Million on Same Class of Drug 10/13/2015 6:52:55 AM
Amgen (AMGN) Release: New Data Show Greater Bone Mineral Density Gains With Prolia (Denosumab) Compared With Zoledronic Acid 10/12/2015 7:01:59 AM
Amgen (AMGN) Announces Repatha Co-Preferred Position On Express Scripts National Formulary 10/7/2015 7:51:18 AM
Amgen (AMGN) Fights Fire with Fire in the Biosimilars Market 10/7/2015 6:23:58 AM
Express Scripts to Cover Amgen (AMGN), Regeneron (REGN)'s Pricey New Cholesterol Drugs 10/7/2015 5:51:34 AM
Amgen (AMGN) To Give 23 Presentations On Osteoporosis Disease And Treatment At American Society For Bone And Mineral Research Annual Meeting 10/6/2015 8:43:49 AM
Amgen (AMGN) To Present At The Barclays Biosimilars Symposium 10/5/2015 7:34:06 AM
Novartis AG (NVS)'s Second Copycat Drug Takes Aim at Amgen (AMGN) Again 10/2/2015 6:21:56 AM